government orders intravenous relenza, page-9

Mal,

excellent post.

This is one of the key problems why we are far away
from a fair shareprice.

Its not only the Nasdaq-listing, its also the fault of
BTA management.

BTA is a great company in terms of Biotech - but in terms
of PR they do almost NOTHING !
Same with GSK.
Vaccine is more important than Relenza for them, look at how
Roche pushes Tamiflu...

Sometimes Im not sure if BTA-management has ever heard of the term "Shareholder Value".

We have much better products than Biocryst, but Biocryst-PR
is 1000 times better than the one of BTA, which is simply
not existing !

I hope that some shareholders will voice their concerns
ref. this matter at the shareholder-meeting next week !